---
title: "Hepalink Files Unaudited First-Quarter 2026 Report With Full Board Approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284551381.md"
description: "Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has filed its unaudited financial results for Q1 2026, with full board approval, emphasizing regulatory compliance and transparency. The board confirmed all directors attended the meeting on April 29, 2026, where the report was approved. The disclosure aligns with Hong Kong securities regulations and highlights management's responsibility for data integrity. The latest analyst rating for the stock (HK:9989) is a Sell, with a price target of HK$4.31, and the company has a market cap of HK$16.62B."
datetime: "2026-04-29T10:23:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284551381.md)
  - [en](https://longbridge.com/en/news/284551381.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284551381.md)
---

# Hepalink Files Unaudited First-Quarter 2026 Report With Full Board Approval

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has provided an update.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd., a Hong Kong-listed PRC pharmaceutical group, has released its unaudited financial results for the first quarter of 2026, prepared under Chinese accounting standards. The company’s board and senior management have formally attested to the truthfulness, accuracy and completeness of the disclosed information, underscoring a focus on regulatory compliance and transparency for investors.

The board confirmed that all directors attended the April 29, 2026 meeting at which the first-quarter report was considered and approved, signalling active governance oversight. The disclosure, made in line with Hong Kong securities regulations, serves primarily as a compliance and governance update rather than a detailed performance snapshot, but reiterates management’s legal responsibility for the integrity of the financial data.

The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.

**More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H**

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a Mainland China-based pharmaceutical company listed in Hong Kong, operating as a joint stock company with limited liability. The group is engaged in the development and production of pharmaceutical products and reports its financial results under PRC Accounting Standards and Accounting Regulations for Business Enterprises.

**Average Trading Volume:** 633,254

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$16.62B

Learn more about 9989 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [09989.HK](https://longbridge.com/en/quote/09989.HK.md)
- [002399.CN](https://longbridge.com/en/quote/002399.CN.md)

## Related News & Research

- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [16:52 ETNexusTek Named a Contender in ISG Provider Lens® Life Sciences Digital Services 2026 Report](https://longbridge.com/en/news/286818120.md)
- [China XLX Announces 2026 Q1 Results | CXLFF Stock News](https://longbridge.com/en/news/286673637.md)
- [NorAm Drilling to present Q1 2026 results in live webcast and Q&A](https://longbridge.com/en/news/287097332.md)
- [J. P. Morgan lowers 2026 gold price forecast](https://longbridge.com/en/news/286714122.md)